<DOC>
	<DOC>NCT00595426</DOC>
	<brief_summary>To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subject is scheduled for elective primary knee arthroplasty Written Informed consent obtained Subject has documented history of previous VTE Subject is considered to be at increased risk of VTE Subject has active bleeding or any condition associated with increased risk of bleeding Subject is planning to have surgery on the contralateral knee at the same time or within 6 weeks after enrollment into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Knee Arthroplasty</keyword>
	<keyword>Factor Xa</keyword>
	<keyword>VTE</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Anticoagulants</keyword>
</DOC>